Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Nitya Raj"'
Autor:
Samagra Jain, Harrison Blume, Lee Rodriguez, Elena Petre, Amgad Moussa, Ken Zhao, Vlasios Sotirchos, Nitya Raj, Diane Reidy, Etay Ziv, Erica Alexander
Publikováno v:
Cancers, Vol 15, Iss 21, p 5202 (2023)
Purpose: This study investigates whether hepatic hilar nerve blocks (HHNB) provide safe, effective analgesia in patients with neuroendocrine tumors (NET) treated with transarterial embolization (TAE). Methods: The retrospective study included all NET
Externí odkaz:
https://doaj.org/article/0b97506fb9504834ab71c894225afc91
Autor:
Pier Selenica, Nitya Raj, Rahul Kumar, David N. Brown, Oriol Arqués, Diane Reidy, David Klimstra, Matija Snuderl, Jonathan Serrano, Héctor G. Palmer, Britta Weigelt, Jorge S. Reis‐Filho, Maurizio Scaltriti
Publikováno v:
Molecular Oncology, Vol 13, Iss 8, Pp 1684-1692 (2019)
Solid pseudopapillary neoplasms (SPNs) are rare and relatively indolent tumors of the pancreas. While primary SPNs can be surgically resected, there are currently no therapies available for patients with advanced stage disease. Given that these tumor
Externí odkaz:
https://doaj.org/article/6576b5b9ce9942dd85b2e2e07c950d78
Autor:
Amy Allen, Alice Can Ran Qin, Nitya Raj, Jiawan Wang, Sharmeen Uddin, Zhan Yao, Laura Tang, Paul A Meyers, Barry S Taylor, Michael F Berger, Rona Yaeger, Diane Reidy-Lagunes, Christine A Pratilas
Publikováno v:
PLoS ONE, Vol 14, Iss 6, p e0217399 (2019)
The clinical significance of BRAF alterations in well-differentiated (WD) metastatic pancreatic neuroendocrine tumor (panNET) is unknown, but BRAF-mutated panNET could represent a subset characterized by an identifiable and clinically actionable driv
Externí odkaz:
https://doaj.org/article/3d6b076143f343139113c9f70bd6622d
Autor:
Nitya Raj, Elizabeth Cruz, Sarah O'Shaughnessy, Claudia Calderon, Joanne F. Chou, Marinela Capanu, Olivia Heffernan, April DeMore, Sippy Punn, Tiffany Le, Haley Hauser, Leonard Saltz, Diane Reidy-Lagunes
Publikováno v:
JCO oncology practice. 18(9)
PURPOSE: Somatostatin analogs octreotide long-acting release (octLAR) and lanreotide are equally acceptable in National Comprehensive Cancer Network guidelines for neuroendocrine tumors (NETs). Lanreotide is more expensive and given by deep subcutane
Autor:
Lisa Bodei, Nitya Raj, Richard K. Do, Audrey Mauguen, Simone Krebs, Diane Reidy-Lagunes, Heiko Schöder
Publikováno v:
Journal of Nuclear Medicine. 64:567-573
Autor:
Nitya Raj, Jennifer A. Chan, Stephanie J. Wang, Rahul R. Aggarwal, Susan Calabrese, April DeMore, Lawrence Fong, Jennifer Grabowsky, Thomas A. Hope, Kanti Pallav Kolli, Claire K. Mulvey, Pamela N. Munster, Kimberly Perez, Sippy Punn, Diane Reidy-Lagunes, Sofia Von Fedak, Li Zhang, Emily K. Bergsland
Publikováno v:
British Journal of Cancer.
Autor:
Jennifer R Eads, Thorvardur R Halfdanarson, Tim Asmis, Andrew M. Bellizzi, Emily K Bergsland, Arvind Dasari, Ghassan El-Haddad, Michael Frumovittz, Joshua Meyer, Erik Mittra, Sten Myrehaug, Eric Nakakura, Nitya Raj, Heloisa P Soares, Brian Untch, Namrata Vijayvergia, Jennifer A Chan
Publikováno v:
Endocrine-Related Cancer.
High grade neuroendocrine tumors (G3 NET) and neuroendocrine carcinomas (NEC) are a rare disease entity for which there is a limited amount of prospective data available. It has also been relatively recent that a distinction has been made between G3
Autor:
Nitya Raj
Publikováno v:
Annals of Surgical Oncology.
Autor:
Wolfgang A. Weber, Lisa Bodei, Christian Lohrmann, Mithat Gönen, Nitya Raj, Jason S. Lewis, Serge K. Lyashchenko, Kevin D. Staton, Simone Krebs, Joseph A. O'Donoghue, Neeta Pandit-Taskar, Diane Reidy-Lagunes
Supplementary Figures 1-5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::026247b896203b3d067c772545da3e4d
https://doi.org/10.1158/1078-0432.22472100.v1
https://doi.org/10.1158/1078-0432.22472100.v1
Autor:
Wolfgang A. Weber, Lisa Bodei, Christian Lohrmann, Mithat Gönen, Nitya Raj, Jason S. Lewis, Serge K. Lyashchenko, Kevin D. Staton, Simone Krebs, Joseph A. O'Donoghue, Neeta Pandit-Taskar, Diane Reidy-Lagunes
Purpose:Radiolabeled somatostatin receptor 2 (SSTR2) antagonists have shown higher tumor uptake and tumor-to-organ ratios than somatostatin agonists in preclinical models of neuroendocrine tumors (NETs). We performed a phase I study to evaluate the s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9481bee6c252d5972ef80194f7fd0e6
https://doi.org/10.1158/1078-0432.c.6528123
https://doi.org/10.1158/1078-0432.c.6528123